Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma

Evaluation of the Effectiveness of YAG Laser Iridotomy in Patients With Primary Angle-Closure: Temporal Peripheral Iridotomy Compared to Inferior Peripheral Iridotomy

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07195370

Acronym

yag laser PI

Enrollment

150

Registered

2025-09-26

Start date

2025-05-01

Completion date

2026-01-01

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma Eye, Angle Closure Glaucoma

Keywords

Primary Angle-Closure Glaucoma

Brief summary

This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Patients visiting the glaucoma clinic at Feiz Hospital who are candidates for peripheral iridotomy will participate. In each patient, one eye will receive a temporal iridotomy, and the other eye will receive an inferior iridotomy, with patients unaware of the location used in each eye. The study will measure outcomes such as laser power, intraocular pressure, visual symptoms, and complications over six months to determine which approach is more effective and safer.

Interventions

OTHERperipheral iridotomy

This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

24 Years to No maximum

Healthy volunteers

Inclusion criteria

Diagnosis of Primary Angle-Closure Glaucoma. Adults (typically over 40 years old). Ability to provide informed consent. Narrow or closed anterior chamber angle (based on gonioscopy). Intraocular pressure (IOP) controlled with medication but requiring surgery. No previous iridotomy.

Exclusion criteria

econdary glaucoma. Active eye diseases (e.g., infection or inflammation). Advanced cataracts or lens-related issues. Severe visual impairment (e.g., less than 20/200 vision). Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease). Pregnancy or breastfeeding. Previous eye surgery (except for minor procedures). Inability to follow-up with scheduled visits. \-

Design outcomes

Primary

Measure	Time frame	Description
adverse events	1 day, 1 week, 1month	Surgical and postoperative complications (e.g., bleeding, infection, or changes in intraocular pressure).

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026